title: Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy.
abstract: OBJECTIVE
  To evaluate the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemo-radiotherapy in patients with resected gastric cancer.
  
  
  METHODS
  We used PCR-RFLP to evaluate the genetic XPD Lys751Gln polymorphisms in 44 patients with stage III (48%) and IV (20%) gastric cancer treated with surgery following radiation therapy plus 5-fluorouracil/leucovorin based chemotherapy.
  
  
  RESULTS
  Statistical analysis showed that 75% (12 of 16) of relapse patients showed Lys/Lys genotype more frequently (P = 0.042). The Lys polymorphism was an independent predictor of high-risk relapse-free survival from Cox analysis (HR: 3.07, 95% CI: 1.07-8.78, P = 0.036) and Kaplan-Meir test (P = 0.027, log-rank test).
  
  
  CONCLUSIONS
  XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to chemo-radiotherapy in resected gastric cancer patients.
authors.affiliation: Laboratory of Biotechnology and Pharmacogenomics, University Clinic of Navarra, Pamplona 31008, Spain. rzarate@unav.es
authors.forename: R N
authors.initials: RN
authors.lastname: Zárate
authors.forename: F
authors.initials: F
authors.lastname: Arias
authors.forename: E
authors.initials: E
authors.lastname: Bandres
authors.forename: E
authors.initials: E
authors.lastname: Cubedo
authors.forename: R
authors.initials: R
authors.lastname: Malumbres
authors.forename: J
authors.initials: J
authors.lastname: García-Foncillas
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003062:Codon / Q000235:genetics; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D013270:Stomach / Q000187:drug effects / Q000528:radiation effects / Q000601:surgery; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D016896:Treatment Outcome; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
chemical_list: D003062:Codon; D051759:Xeroderma Pigmentosum Group D Protein; D002955:Leucovorin; D005472:Fluorouracil